SINT (SINTX Technologies) EBIT: $-10.84 Mil (TTM As of Mar. 2026)

What is SINTX Technologies EBIT?

SINTX Technologies SINT +3.78% 27 EBIT is $-10.84 Mil as of Mar. 2026. GuruFocus rates SINT with a GF Score™ of 27/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

SINTX Technologies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SINTX Technologies's annualized ROC % for the quarter that ended in Mar. 2026 was -197.64%. SINTX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -392.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SINTX Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -81.63%.

SINTX Technologies (NAS:SINT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SINTX Technologies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-12.828 * ( 1 - 0% )	/	( (6.785	+	6.196)	/ 2 )
=	-12.828	/	6.4905
=	-197.64 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.506	-	0.804	-	( 4.14	-	max(0, 3.733	-	5.65	+	4.14	))
=	6.785

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.811	-	1.463	-	( 1.889	-	max(0, 4.172	-	4.324	+	1.889	))
=	6.196

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

SINTX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.236	/	( ( (2.934 + max(-1.818, 0))	+	(2.793 + max(-1.209, 0)) )	/	2 )
=	-11.236	/	( ( 2.934	+	2.793 )	/	2 )
=	-11.236	/	2.8635
=	-392.39 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.178	+	0.825	+	0.507)	-	(0.804	+	0	+	2.524)
=	-1.818

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.364	+	1.394	+	0.677)	-	(1.463	+	0	+	2.181)
=	-1.209

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SINTX Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-10.842	/	13.282
	=	-81.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SINTX Technologies EBIT Related Terms

SINTX Technologies EBIT Historical Data

* Premium members only.

The historical data trend for SINTX Technologies's EBIT can be seen below:

SINTX Technologies EBIT Chart

SINTX Technologies Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-9.28

-12.02

-8.26

-11.00

-10.31

SINTX Technologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-2.28	-2.30	-3.53	-2.20	-2.81

SINT vs VVOS, AIDX, ALUR: EBIT Comparison

For the Medical Devices subindustry, SINTX Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SINTX Technologies EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SINTX Technologies's EV-to-EBIT falls into.

Save Embed

27GF Score

SINTX Technologies Inc SINT

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

SINTX Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.84 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-10.84 Mil mean?

SINTX Technologies (SINT) has a EBIT of $-10.84 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SINTX Technologies.

Is SINTX Technologies' EBIT too high?

SINTX Technologies' current EBIT is $-10.84 Mil. Overall, SINTX Technologies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does SINTX Technologies' EBIT compare to VVOS and AIDX?

SINTX Technologies' EBIT of $-10.84 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SINTX Technologies. SINTX Technologies's current EBIT is $-10.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is SINTX Technologies stock overvalued right now?

Based on GuruFocus' analysis, SINTX Technologies (SINT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.93 — trading 1186.7% above its estimated fair value. The current EBIT is $-10.84 Mil. SINTX Technologies' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For SINTX Technologies (SINT), the current EBIT is $-10.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SINTX Technologies (SINT) Overvalued in 2026?

Based on GuruFocus' analysis, SINTX Technologies stock appears to be overvalued. The current stock price of $1.93 is trading 1186.7% above its estimated GF Value™ of $0.15. GuruFocus considers SINTX Technologies to be Significantly Overvalued.

Key valuation signals for SINT:

EBIT: $-10.84 Mil
GF Value™: $0.15 vs. price of $1.93 (1186.7% above fair value)
GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the SINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SINTX Technologies Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies VVOS AIDX ALUR POAS USAQ TNON ALRTF NVNO BMRA STME ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges 0A8S:UK

Address 1885 West 2100 South, Salt Lake City, UT, USA, 84119

Website https://www.sintx.com

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

27GF Score

Get the complete analysis for SINT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93

Price

$0.15

GF Value

View SINT Analysis

See EBIT data for all stocks →